CoChat

Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease

Open access
Zhang, Liming, Lei, Qian, Wang, Hongxiang, Xu, Cuiwei, Liu, Teng, Kong, Fancong, Yang, Cui, Yan, Guoxin, Sun, Li, Zhao, Aiqi, Chen, Wenlan, Hu, Yu, Xie, Hui, Cao, Yulin, Fu, Fenfen, Yuan, Guolin, Chen, Zhichao, Guo, An-Yuan, Li, Qiubai · 2019 · Theranostics
Cited by 71

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: As a hallmark driver of multiple myeloma (MM), MM bone disease (MBD) is unique in that it is characterized by severely impaired osteoblast activity resulting from blocked osteogenesis in bone marrow-derived mesenchymal stem cells (BM-MSCs).The mechanisms underlying this preferential blockade are incompletely understood.Methods: miRNA expression of MM cell-derived extracellular vesicles (MM-EVs) was detected by RNA sequencing.MM-EVs impaired osteogenesis and exacerbated MBD were in vitro and in vivo validated by histochemical staining, qPCR and micro-CT.We additionally examined the correlation between CD138 + circulating EVs (cirEVs) count and bone lesion in de novo MM patients.Results: Here, by sequencing and bioinformatics analysis, we found that MM-EVs were enriched in various molecules negatively regulating osteogenesis.We experimentally verified that MM-EVs inhibited BM-MSC osteogenesis, induced elevated expression of miR-103a-3p inhibiting osteogenesis in BM-MSCs, and increased cell viability and interleukin-6 secretion in MM cells.In a mouse model, MM-EVs that were injected into the marrow space of the left tibia led to impaired osteogenesis and exacerbated MBD and MM progression.Furthermore, the levels of CD138 + cirEVs in the peripheral blood were positively correlated with the number of MM bone lesions in MM patients.Conclusions: These findings suggest that MM-EVs play a pivotal role in the development of severely impaired osteoblast activity, which represents a novel biomarker for the precise diagnosis of MBD and a compelling rationale for exploring MM-EVs as a therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.27550

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Communication by Extracellular Vesicles: Where We Are and Where We Need to Go

    Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444 · cited 1×

    “Recently, a growing body of evidence has shown that extracellular vesicles (EVs) are a previously unappreciated mechanism for intercellular communication, and cancer cells can release EVs that contain a variety of molecules, such as proteins, RNAs and microRNAs (miRNAs), to influence the microenvironment [14-20].”
    Background
  • Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

    Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175 · cited 1×

    “The key roles of these miRNAs enriched in EVs that are specifically released by parental cells and transferred to target cells have also been demonstrated by many studies [43-47].”
    BackgroundSelf-citation
  • Biological and therapeutic impact of intratumor heterogeneity in cancer evolution

    McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077 · cited 2×

    “MM cells develop via forward-feedback mechanisms with local BM-MSCs, and the cycle of interactions between MM cells and BM-MSCs contributes to the incurability of MBD and myeloma [1, 10, 12, 13].”
    Background
  • Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921 · cited 1×

    “Currently, there is an ongoing dilemma in the management of patients with smoldering MM (SMM), which is an intermediate clinically-defined stage associated with a much higher risk of progression to malignancy (~10% per year) than monoclonal gammopathy of undetermined significance (MGUS; ~1% per year) [54, 55].”
    Background
  • Osteoblast and osteocyte: Games without frontiers

    Capulli, M., Paone, R., & Rucci, N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.003 · Cited by 413 · cited 11×

    “To observe the uptake of MM-EVs into the BM-MSCs or MM cells, the MM-EVs were stained with PKH26 (1 μM), and the cells were then incubated with the PKH26-stained MM-EVs for 2, 4, 6, 12 or 24 h at 37 °C.”
    BackgroundInfluential
  • The osteoblastic niche in the context of multiple myeloma

    Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., & Giuliani, N. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12578 · Cited by 52 · cited 2×

    “bortezomib, the mainstay treatments for MBD, bone fractures and osteoporosis continue to persist, and the devastating skeletal complications associated with this disease are a significant cause of morbidity and mortality in MM patients [4-7].”
    Background

Show all 6 references

Cited by

Metadata

Authors
Zhang, L., Lei, Q., Wang, H., Xu, C., Liu, T., Kong, F., Yang, C., Yan, G., Sun, L., Zhao, A., Chen, W., Hu, Y., Xie, H., Cao, Y., Fu, F., Yuan, G., Chen, Z., Guo, A.-Y., & Li, Q.
Venue
Theranostics
Published
2019
Volume
9
Issue
1
Pages
196-209
ISSN
1838-7640 (ISSN-L)
OpenAlex
W2904267251
Cited by
71
References
6
FWCI
5.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.